Chater, Peter I., Matthew D. Wilcox, and Jeffrey P. Pearson. “Efficacy and safety concerns over the use of mucus modulating agents for drug delivery using nanoscale systems.” Advanced drug delivery reviews (2017).
Crouch LI, Liberato MV, Urbanowicz PA, Baslé A, Lamb CA, Stewart CJ, Cooke K, Doona M, Needham S, Brady RR, Berrington JE., Madunic k,, Wuhrer M, Chater P, Pearson J, Bolam D. “Prominent members of the human gut microbiota express endo-acting O-glycanases to initiate mucin breakdown.” Nature communications (2020).
Prüfert, Felix, Sonja Bonengel, Saskia Köllner, Janine Griesser, Matthew D. Wilcox, Peter I. Chater, Jeffrey P. Pearson, and Andreas Bernkop-Schnürch. “ζ potential changing nanoparticles as cystic fibrosis transmembrane conductance regulator gene delivery system: an in vitro evaluation.” Nanomedicine 12, no. 22 (2017): 2713-2724.
Pearson, Jeffrey P., Peter I. Chater, and Matthew D. Wilcox. “The properties of the mucus barrier, a unique gel–how can nanoparticles cross it?.” Therapeutic delivery 7, no. 4 (2016): 229-244.
Wilcox, M. D., L. K. Van Rooij, P. I. Chater, I. Pereira de Sousa, and J. P. Pearson. “The effect of nanoparticle permeation on the bulk rheological properties of mucus from the small intestine.” European Journal of Pharmaceutics and Biopharmaceutics 96 (2015): 484-487.